论文部分内容阅读
美国食品与药品监督管理局(FDA)于2014年4月关于电动子宫分碎器在子宫肌瘤微创手术中应用的声明引起了妇科学界的热议。该声明关注了一个焦点话题:肿瘤的腹腔播散将使预后不良。因此,避免分碎器在明确或可疑子宫恶性肿瘤的患者中使用是合理的忠告。另外,术前筛查患者常见(年龄的增长、绝经状态)及罕见[儿童期视网膜母细胞瘤史、他莫昔芬用药史、遗传性子宫平滑肌瘤病肾癌(HLRCC)综合征]肉瘤危险因素也十
The FDA statement of April 2014 on the use of electric uterine shredding in minimally invasive surgery for uterine fibroids has sparked a heated debate among gynecologists. The statement focused on a focused topic: the tumor’s abdominal cavity dissemination will make the prognosis is poor. Therefore, avoiding the use of splitters in patients with clear or suspected uterine malignancies is a reasonable advice. In addition, patients with preoperative screening (age, menopausal status) and rare (history of childhood retinoblastoma, history of tamoxifen use, hereditary uterine leiomyomancer renal cell carcinoma (HLRCC) syndrome] sarcoma The risk factor is also ten